BAJAJ BROKING

Notification
No new Notification messages
Wagons Learning IPO is Open!
Apply for the Wagons Learning IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

10440

500257

LUPIN

img img img img
No Data Available

Experience smart and hassle-free investing in minutes with Bajaj Broking! *T&C apply

LUPIN LIMITED performance

Today’s low

Today’s high

₹ 2070.90 ₹ 2117.00
₹ 2095.60

52 week low

52 week high

₹ 1493.30 ₹ 2402.90
₹ 2095.60

Open Price

₹ 2071.00

Prev. Close

₹ 2067.10

Volume (Shares)

1018611.00

Total traded value

₹ 21346.01

Upper Circuit

₹ 2273.80

Lower Circuit

₹ 1860.40

info

LUPIN LIMITED Share Price Update

As of the latest trading session, LUPIN LIMITED share price is currently at ₹ 2095.6, which is up by ₹ 28.50 from its previous closing. Today, the stock has fluctuated between ₹ 2070.90 and ₹ 2117.00. Over the past year, LUPIN LIMITED has achieved a return of 27.32 %. In the last month alone, the return has been 7.16 %. Read More...

LUPIN LIMITED fundamentals


  • Market cap (Cr)

    95,492.08

  • P/E Ratio (TTM)

    31.19

  • Beta

    0.69

  • Book Value / share

    481.38

  • Return on equity

    11.92%

  • EPS (TTM)

    68.52

  • Dividend yield

    0.38%

  • Net profit/quarter (Cr)

    984.67

info icon alternate text
  • Market cap (Cr)

    95,448.78

  • P/E Ratio (TTM)

    31.19

  • Beta

    0.65

  • Book Value / share

    481.38

  • Return on equity

    11.92%

  • EPS (TTM)

    68.52

  • Dividend yield

    0.38%

  • Net profit/quarter (Cr)

    984.67

info icon alternate text

LUPIN LIMITED Financials

  • Key Results

  • Key Ratios

  • Balance sheet

  • Cash Flow

  • Competition

info-icon

Revenue

Net income

Particulars DEC 2024 (Values in Cr)
Revenue 4060.16
Operating Expense 2969.02
Net Profit 984.67
Net Profit Margin (%) 24.25
Earnings Per Share (EPS) 21.58
EBITDA 1389.12
Effective Tax Rate (%) 19.09
Particulars SEP 2024 (Values in Cr)
Revenue 3931.73
Operating Expense 3154.77
Net Profit 807.76
Net Profit Margin (%) 20.54
Earnings Per Share (EPS) 17.71
EBITDA 1147.37
Effective Tax Rate (%) 17.91
Particulars JUN 2024 (Values in Cr)
Revenue 4084.00
Operating Expense 3122.93
Net Profit 889.18
Net Profit Margin (%) 21.77
Earnings Per Share (EPS) 19.51
EBITDA 1237.89
Effective Tax Rate (%) 17.89
Particulars MAR 2024 (Values in Cr)
Revenue 3331.72
Operating Expense 2999.06
Net Profit 384.08
Net Profit Margin (%) 11.52
Earnings Per Share (EPS) 8.43
EBITDA 731.69
Effective Tax Rate (%) 10.29
Particulars DEC 2023 (Values in Cr)
Revenue 3999.47
Operating Expense 3054.95
Net Profit 916.44
Net Profit Margin (%) 22.91
Earnings Per Share (EPS) 20.14
EBITDA 1240.50
Effective Tax Rate (%) 15.45
Particulars MAR 2024 (Values in Cr)
Revenue 14316.43
Operating Expense 11988.54
Net Profit 2326.09
Net Profit Margin (%) 16.24
Earnings Per Share (EPS) 51.10
EBITDA 3565.79
Effective Tax Rate (%) 16.46
Particulars MAR 2023 (Values in Cr)
Revenue 11043.07
Operating Expense 10822.95
Net Profit 425.21
Net Profit Margin (%) 3.85
Earnings Per Share (EPS) 9.35
EBITDA 1173.92
Effective Tax Rate (%) 19.33
Particulars MAR 2022 (Values in Cr)
Revenue 11258.48
Operating Expense 12083.61
Net Profit -188.70
Net Profit Margin (%) -1.67
Earnings Per Share (EPS) -4.16
EBITDA 426.13
Effective Tax Rate (%) -16.82
Particulars MAR 2021 (Values in Cr)
Revenue 10901.02
Operating Expense 9555.32
Net Profit 1258.62
Net Profit Margin (%) 11.54
Earnings Per Share (EPS) 27.77
EBITDA 2173.15
Effective Tax Rate (%) 22.76
Particulars MAR 2020 (Values in Cr)
Revenue 10805.83
Operating Expense 9689.39
Net Profit 727.55
Net Profit Margin (%) 6.73
Earnings Per Share (EPS) 16.07
EBITDA 1623.59
Effective Tax Rate (%) 30.85
Particulars MAR 2024 (Values in Cr)
Book Value / Share 452.12
ROE % 11.92
ROCE % 13.96
Total Debt to Total Equity 0.02
EBITDA Margin 24.31
Particulars MAR 2023 (Values in Cr)
Book Value / Share 404.66
ROE % 2.33
ROCE % 3.21
Total Debt to Total Equity 0.05
EBITDA Margin 10.43
Particulars MAR 2022 (Values in Cr)
Book Value / Share 399.34
ROE % -1.19
ROCE % -0.61
Total Debt to Total Equity 0.04
EBITDA Margin 3.36
Particulars MAR 2021 (Values in Cr)
Book Value / Share 409.20
ROE % 6.98
ROCE % 8.95
Total Debt to Total Equity 0.01
EBITDA Margin 19.66
Particulars MAR 2020 (Values in Cr)
Book Value / Share 385.72
ROE % 6.67
ROCE % 9.95
Total Debt to Total Equity 0.00
EBITDA Margin 20.66
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 1202.54
Total Assets 23997.18
Total Liabilities 23997.18
Total Equity 14373.45
Share Outstanding 455678908
Price to Book Ratio 3.58
Return on Assets (%) 7.97
Return on Capital (%) 11.23
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 1293.13
Total Assets 22955.93
Total Liabilities 22955.93
Total Equity 12542.82
Share Outstanding 454981335
Price to Book Ratio 1.60
Return on Assets (%) 1.87
Return on Capital (%) 2.56
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 1098.13
Total Assets 21821.22
Total Liabilities 21821.22
Total Equity 12221.98
Share Outstanding 454475014
Price to Book Ratio 1.87
Return on Assets (%) -7.00
Return on Capital (%) -9.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1742.46
Total Assets 23610.44
Total Liabilities 23610.44
Total Equity 13858.11
Share Outstanding 453680133
Price to Book Ratio 2.49
Return on Assets (%) 5.15
Return on Capital (%) 6.53
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 2454.30
Total Assets 24983.85
Total Liabilities 24983.85
Total Equity 12581.16
Share Outstanding 452998121
Price to Book Ratio 1.53
Return on Assets (%) -1.07
Return on Capital (%) -1.6
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 138.64
Total Assets 24922.86
Total Liabilities 24922.86
Total Equity 20603.09
Share Outstanding 455678908
Price to Book Ratio 3.58
Return on Assets (%) 9.33
Return on Capital (%) 11.28
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 100.97
Total Assets 22683.67
Total Liabilities 22683.67
Total Equity 18411.86
Share Outstanding 454981335
Price to Book Ratio 1.60
Return on Assets (%) 1.87
Return on Capital (%) 2.23
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 64.56
Total Assets 22313.37
Total Liabilities 22313.37
Total Equity 18150.19
Share Outstanding 454475014
Price to Book Ratio 1.87
Return on Assets (%) -0.84
Return on Capital (%) -1
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 284.01
Total Assets 21858.56
Total Liabilities 21858.56
Total Equity 18565.57
Share Outstanding 453680133
Price to Book Ratio 2.49
Return on Assets (%) 5.75
Return on Capital (%) 6.67
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 1305.93
Total Assets 20680.50
Total Liabilities 20680.50
Total Equity 17473.20
Share Outstanding 452998121
Price to Book Ratio 1.53
Return on Assets (%) 3.51
Return on Capital (%) 4.16
Particulars MAR 2024 (Values in Cr)
Net Income 2422.27
Cash from Operations 3974.41
Cash from Investing -1712.20
Cash from Financing -2184.21
Net change in Cash -248.05
Free Cash Flow 4903.30
Particulars MAR 2023 (Values in Cr)
Net Income 716.49
Cash from Operations 2140.42
Cash from Investing -1286.77
Cash from Financing -337.25
Net change in Cash 273.22
Free Cash Flow 3640.04
Particulars MAR 2022 (Values in Cr)
Net Income -1372.21
Cash from Operations 320.43
Cash from Investing 1292.23
Cash from Financing -1572.32
Net change in Cash 87.22
Free Cash Flow 1225.51
Particulars MAR 2021 (Values in Cr)
Net Income 1676.45
Cash from Operations 2517.12
Cash from Investing -1239.58
Cash from Financing -1885.27
Net change in Cash -1303.09
Free Cash Flow 3194.74
Particulars MAR 2020 (Values in Cr)
Net Income 876.78
Cash from Operations 1980.05
Cash from Investing 1106.99
Cash from Financing -890.58
Net change in Cash 1685.25
Free Cash Flow 2653.18
Particulars MAR 2024 (Values in Cr)
Net Income 2784.69
Cash from Operations 2650.78
Cash from Investing -1599.02
Cash from Financing -867.07
Net change in Cash 38.04
Free Cash Flow 3349.32
Particulars MAR 2023 (Values in Cr)
Net Income 527.14
Cash from Operations 1920.79
Cash from Investing -1269.17
Cash from Financing -498.26
Net change in Cash 26.56
Free Cash Flow 2495.92
Particulars MAR 2022 (Values in Cr)
Net Income -161.53
Cash from Operations 2.86
Cash from Investing -371.79
Cash from Financing 102.45
Net change in Cash -118.31
Free Cash Flow 600.06
Particulars MAR 2021 (Values in Cr)
Net Income 1629.70
Cash from Operations 1998.72
Cash from Investing -2507.52
Cash from Financing -53.17
Net change in Cash -990.61
Free Cash Flow 2518.55
Particulars MAR 2020 (Values in Cr)
Net Income 1052.25
Cash from Operations 2605.41
Cash from Investing -739.56
Cash from Financing -367.85
Net change in Cash 1112.08
Free Cash Flow 3123.52
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 19.60 1.99 279.41 34.11 / 77.70
BLISS GVS PHARMA LTD 119.00 15.60 1.24 1253.91 92.25 / 184.95
CIPLA LTD 1549.65 25.08 4.41 125155.99 1310.05 / 1702.00
FERMENTA BIOTECH LIMITED 260.70 21.60 2.64 767.27 145.00 / 449.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 36.46 21.96 6.19 279.41 34.11 / 77.70
AMRUTAJAN HEALTH LTD 692.80 40.61 6.72 2002.93 548.05 / 861.40
ASTRAZENECA PHARMA IND LT 8665.50 129.24 31.88 21663.75 5000.00 / 9199.00
BLISS GVS PHARMA LTD 119.00 15.45 1.22 1253.91 92.25 / 184.95

LUPIN LIMITED Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
2095.60 1.37 redarrow
red-green-graph indicator
0 Bearish
16 Bullish
  • 5 Days 2074.70
  • 26 Days 2030.50
  • 10 Days 2053.90
  • 50 Days 2034.80
  • 12 Days 2048.00
  • 100 Days 2050.50
  • 20 Days 2034.50
  • 200 Days 1990.20
2078.73 PIVOT

First Support

2041.57

First Resistance

2104.27

Second Support

2016.03

Second Resistance

2141.43

Third Support

1978.87

Third Resistance

2166.97

RSI

55.40

ADX

10.36

MACD

17.55

Williams % R

-22.32

Commodity Channel Index (CCI)

101.60

Date

2025-04-30

Week

547107.00

Same Day

551737.00

Month

736833.00

1 Year

0.70

3 Year

0.65

Over 1 Month

7.16%

down

Over 1 Year

27.32%

down

Over 3 Months

1.51%

down

Over 3 Years

41.36%

down

Over 6 Months

-2.90%

down

Over 5 Years

20.19%

down

Invest with Confidence

Left Arrow
MTF boost
Buy Now. Pay Later

Boost your capital upto 5 X

img
IPO boost
Invest in IPOs
They give good returns
img
Right Arrow

LUPIN LIMITED shareholding pattern

  • Shareholding Summary

  • Historical Promotor Holding

  • Historical MF Holding

  • Historical FII Holding

Holding

Others
6.21%
Promoter Holdings
46.91%
FII
21.46%
DII
25.4%
Promoter Shares(Pledge Percentage)
0.0%
Name Shares Category
Lupin Investments Pvt Ltd 2.0719439E8 (45.38%) Shareholding of Promoter and Promoter Group
Hdfc Trustee Company Ltd-hdfc Balanced Advantage Fund 1.470667E7 (3.22%) Public Shareholding
Icici Prudential Value Discovery Fund 1.199626E7 (2.63%) Public Shareholding
Life Insurance Corporation Of India 9367533.0 (2.05%) Public Shareholding
Nippon Life India Trustee Ltd. A/c Nippon India Growth Fund 8583097.0 (1.88%) Public Shareholding
Sbi Long Term Equity Fund 7380503.0 (1.62%) Public Shareholding
Axis Mutual Fund Trustee Limited A/c Axis Mutual Fund A/c Axis Midcap Fund 7022085.0 (1.54%) Public Shareholding
Nps Trust-a/c Hdfc Pension Fund Management Limited Scheme E 6492958.0 (1.42%) Public Shareholding
Mirae Asset Large And Midcap Fund 6495736.0 (1.42%) Public Shareholding
Hdfc Life Insurance Company Limited 5997345.0 (1.31%) Public Shareholding
Sbi Life Insurance Co. Ltd. 4886080.0 (1.07%) Public Shareholding
Manju D Gupta 3871162.0 (0.85%) Shareholding of Promoter and Promoter Group
Nilesh D Gupta 901064.0 (0.2%) Shareholding of Promoter and Promoter Group
Anuja Gupta 725705.0 (0.16%) Shareholding of Promoter and Promoter Group
Desh Bandhu Gupta Huf 647580.0 (0.14%) Shareholding of Promoter and Promoter Group
Vinita Gupta 327424.0 (0.07%) Shareholding of Promoter and Promoter Group
Richa Gupta 233265.0 (0.05%) Shareholding of Promoter and Promoter Group
Kavita Gupta 200170.0 (0.04%) Shareholding of Promoter and Promoter Group
Veda Nilesh Gupta 74554.0 (0.02%) Shareholding of Promoter and Promoter Group
Neel Deshbandhu Gupta 29448.0 (0.01%) Shareholding of Promoter and Promoter Group
Manju D Gupta (as A Trustee Of Gupta Family Trust) 1000.0 (0.0%) Shareholding of Promoter and Promoter Group
Shefali Nath Gupta 1752.0 (0.0%) Shareholding of Promoter and Promoter Group

News

Left Arrow
Right Arrow

LUPIN LIMITED corporate actions

  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Jul 2023 4.0 Final 14 Jul 2023 Equity shares
14 Jul 2022 4.0 Final 15 Jul 2022 Equity shares
27 Jul 2021 6.5 Final 28 Jul 2021 Equity shares
03 Aug 2020 6.0 Final 05 Aug 2020 Equity shares
29 Jul 2019 5.0 Final 31 Jul 2019 Equity shares
30 Jul 2018 5.0 Final 01 Aug 2018 Equity shares
24 Jul 2017 7.5 Final 26 Jul 2017 Equity shares
25 Jul 2016 7.5 Final 27 Jul 2016 Equity shares
14 Jul 2015 7.5 Final 16 Jul 2015 Equity shares
21 Jul 2014 3.0 Final 23 Jul 2014 Equity shares
13 Feb 2014 3.0 Interim 14 Feb 2014 Equity shares
29 Jul 2013 4.0 Final 31 Jul 2013 Equity shares
13 Jul 2012 3.2 Final 17 Jul 2012 Equity shares
18 Jul 2011 3.0 Final 20 Jul 2011 Equity shares
19 Jul 2010 13.5 Final 21 Jul 2010 Equity shares
20 Jul 2009 12.5 Final 22 Jul 2009 Equity shares
11 Jul 2008 5.0 Final 15 Jul 2008 Equity shares
11 Jul 2008 5.0 Special 15 Jul 2008 Equity shares
10 Jul 2007 5.0 Final 12 Jul 2007 Equity shares
15 Jul 2005 0.0 Final 19 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
14 Aug 2006 11 Aug 2006 1:1
Ex-Date Old FV NEW FV Record Date
27 Aug 2010 10.0 2.0 30 Aug 2010
  • Dividend

  • Bonus

  • Split

Dividend date Dividend amount Dividend type Record date Instrument type
14 Jul 2023 4.0 Final 14 Jul 2023 Equity shares
14 Jul 2022 4.0 Final 15 Jul 2022 Equity shares
27 Jul 2021 6.5 Final 28 Jul 2021 Equity shares
03 Aug 2020 6.0 Final 05 Aug 2020 Equity shares
29 Jul 2019 5.0 Final 31 Jul 2019 Equity shares
30 Jul 2018 5.0 Final 01 Aug 2018 Equity shares
24 Jul 2017 7.5 Final 26 Jul 2017 Equity shares
25 Jul 2016 7.5 Final 27 Jul 2016 Equity shares
14 Jul 2015 7.5 Final 16 Jul 2015 Equity shares
21 Jul 2014 3.0 Final 23 Jul 2014 Equity shares
13 Feb 2014 3.0 Interim 14 Feb 2014 Equity shares
29 Jul 2013 4.0 Final 31 Jul 2013 Equity shares
13 Jul 2012 3.2 Final 17 Jul 2012 Equity shares
18 Jul 2011 3.0 Final 20 Jul 2011 Equity shares
19 Jul 2010 13.5 Final 21 Jul 2010 Equity shares
20 Jul 2009 12.5 Final 22 Jul 2009 Equity shares
11 Jul 2008 5.0 Final 15 Jul 2008 Equity shares
11 Jul 2008 5.0 Special 15 Jul 2008 Equity shares
10 Jul 2007 5.0 Final 12 Jul 2007 Equity shares
15 Jul 2005 0.0 Final 19 Jul 2005 Equity shares
Ex-Date Ex-Bonus Ratio
14 Aug 2006 11 Aug 2006 1:1
Ex-Date Old FV NEW FV Record Date
27 Aug 2010 10.0 2.0 30 Aug 2010

Lupin Share Result Highlights

Metric

Value

Lupin Share Price

₹2015.85

Change

-₹23.15 (-1.13%)

52-Week Range

₹1153.55 – ₹2312.00

Net Profit (Qtr)

₹807.76 crore

Net Profit Margin

20.54%

Earnings Per Share (EPS)

₹17.71

Revenue (Qtr)

₹3931.73 crore

EBITDA

₹1147.37 crore

Operating Expense

₹3154.77 crore

Key Highlights:

  • Lupin share price has decreased by ₹23.15, reflecting a decline of 1.13%.

  • Lupin future share price trends indicate a potential rise to ₹2018.80 by 28 Nov 2024.

  • The company has shown consistent profitability with a robust net profit of ₹807.76 crore for the quarter.

Lupin Share Annual Reports

Year

Dividend

EPS

Net Profit

Revenue

Sep 2024

₹4 (Final)

₹17.71

₹807.76 crore

₹3931.73 crore

Sep 2023

₹4 (Final)

₹16.51

₹758.41 crore

₹3682.24 crore

Sep 2022

₹4 (Final)

₹15.30

₹733.92 crore

₹3451.56 crore

Key Highlights:

  • Lupin share price remains stable despite slight fluctuations in earnings.

  • The company has consistently delivered a solid net profit growth year on year.

  • The annual reports reflect a strong revenue trajectory and dividend policy.

Lupin Share Dividend

Year

Dividend Amount

Dividend Type

Ex-Date

2023

₹4

Final

14 Jul 2023

2022

₹4

Final

14 Jul 2022

2021

₹6.5

Final

27 Jul 2021

2020

₹6

Final

03 Aug 2020

Key Highlights:

  • Lupin share dividend for 2023 was ₹4 per share, a consistent payout policy.

  • The company has maintained a steady dividend record, reinforcing investor confidence in the Lupin share price.

Popular FAQs

1. Who is the CEO of Lupin Ltd?

As of now, the CEO of Lupin Ltd is Vinita Gupta, who has been leading the company through various strategic expansions and acquisitions.

 

2. When was Lupin Ltd established?

Lupin Ltd was established in 1983 under the name Lupin Chemicals Ltd before it was later renamed Lupin Ltd in 2001.

 

3. What factors influence the Lupin Share Price?

The Lupin share price is influenced by several factors including the company’s financial performance, market conditions, product approvals, regulatory news (particularly from the US FDA), acquisitions, partnerships and the performance of key therapeutic segments such as cardiovascular, anti-TB and generic drugs. Additionally, global market conditions and the company’s expansion into emerging markets also play a role.

 

4. Is Lupin Ltd debt-free?

Lupin Ltd is not debt-free. However, like many large pharmaceutical companies, Lupin manages its debt levels based on capital requirements for expansion and R&D. The company's debt position can be subject to fluctuations depending on acquisitions and investments in new products or markets.

 

5. What is the CAGR of Lupin Share?

The Compound Annual Growth Rate (CAGR) of Lupin's share price over various periods is 3% over 10 years, 22% over 5 years, 29% over 3 years and 69% over the past year, reflecting a strong recent performance in comparison to its longer-term growth trajectory.

 

6. How has the Lupin Share Price performed over the past year?

Lupin’s share price has experienced fluctuations over the past year, influenced by various factors including product launches, regulatory approvals and acquisitions. Specific details about its performance can be found by analysing recent market data or consulting financial reports.

LUPIN LIMITED Share Price

Lupin is an innovation led Transnational Pharmaceutical Company producing, developing and marketing a wide range of branded & generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally. The Company has significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, Central Nervous System (CNS), Gastro-Intestinal (GI), Anti-Infective and Nonsteroidal Anti Inflammatory Drug (NSAID) therapy segments and is a global leader in the Anti-TB and Cephalosporins segments.

Lupin Limited was incorporated in the year 1983 with the name Lupin Chemicals Limited. In March 2001, Lupin Laboratories Limited was amalgamated with the company and the name was changed to Lupin Limited. In the year 1987, the company commenced operations in Cephalexin Plant at Mandideep and 7 ADCA plant at Ankleshwar. In the year 1989, the company established a joint venture in Thailand, namely Lupin Chemicals (Thailand) Ltd. In the year 1991, they initiated production of Injectable cephalosporin (bulk and dosages) at Mandideep. In the year 1992, the company set up Fermentation Plant at Tarapur, Maharashtra. Also, Sterile Plant for injectable Cephalosporins (bulk) was commissioned at Mandideep.

They commenced supply of Cephalosporin bulk actives to their alliance partners in the US. Also, they commissioned a state of the art US FDA approvable oral cephalosporin bulk active plant. In the year 2002, the company commissioned the new Anti-TB facility at Aurangabad. In the year 2003, they formed Lupin Pharmaceuticals Inc. USA, for trading, marketing and developmental activities in the US. In the year 2006, the company set up a new facility at Jammu.

In the year 2007, the company acquired Vadodara based Rubamin Laboratories Ltd (rechristened to Novodigm Ltd). Also, they acquired Kyowa Pharmaceutical Industry Company Limited, a leading Generic Company in Japan. They started commercial production at their newly finished dosage facility at Jammu. Also, they set a new finished dosage facility at Indore.

During the year 2008-09, the company expanded their product basket in Japan-Kyowa and received ten products approval from Ministry of Health & Labour Welfare, Japan. They acquired 100% stake in Hormosan Pharma GmbH, a generic company in Germany. Also, they acquired 36.65% stake in Generic Health Pty Ltd., in Australia, 60% stake in Pharma Dynamics in South Africa and 51% stake in Multicare Pharmaceuticals Philippines Inc in Philippines.

During the year 2009-10, Lupin (Europe) Ltd, UK and Lupin Pharma Canada Ltd, Canada were incorporated on June 5, 2009 and June 18, 2009 respectively. Lupin Holding B V, the Netherlands transferred their holdings in Max Pharma Pty Ltd, Australia, a wholly owned subsidiary of the company to Generic Healthy Pty Ltd, Australia, an associated of the company upon which Max Pharma Pty Ltd ceased to be a subsidiary of the company with effect from May 31, 2009. In January 2010, as per the scheme of amalgamation, Novodigm Ltd, Lupin Pharmacare Ltd and Lupin Herbal Ltd, wholly owned subsidiaries of the company were amalgamated with the company with effect from April 1, 2009.

In August 23, 2010, the company incorporated Lupin Mexico SA de CV, Mexico as a subsidiary company. The company increased their stake in Generic Health Pty Ltd., (Generic), Australia, from 49.91% to 76.65% and thus Generic became a subsidiary of the company with effect from September 27, 2010. Consequently, Bellwether Pharma Pty Ltd., Australia, Generic Health Inc., U.S.A. and Max Pharma Pty Ltd., Australia, which were subsidiaries of Generic, became subsidiaries of the company with effect from September 27, 2010. The company incorporated Lupin Philippines, Inc., Philippines and Lupin Healthcare Ltd., India, as subsidiaries on December 20, 2010 and March 17, 2011 respectively.

In June 2011, the company's Generic Healthy Pty Ltd acquired worldwide rights for the Goanna Brand and the complete range of premium therapeutic oils, rubs and ointments marketed under the brand. In July 2011, the company entered into a research and development agreement with Medicis Pharmaceutical Corporation (Medicis) to apply Lupin technologies to multiple therapeutic compounds. In November 2011, the company acquired I'rom Pharmaceuticals through their Japanese subsidiary.

In 2012, the company receives Tentative Approval for Generic Glumetza Extended-Release Tablets. The company announces settlement with SANTARUS and DEPOMED for GLUMETZA Patent Litigation. The company also launches Generic Geodon Capsules and Generic SEROQUEL Tablets during the year under review.

In 2013, the company inaugurated new Plant at Nagpur. The company got Mahindra Samridhhi India Agri National Award for Bee keeping and Honey Production.

In 2014, the company acquired Laboratorios Grin S.A. De C.V., Mexico; a Specialty Ophthalmic Company. The company enters the Latin American Market. The company also acquires Nanomi B.V. and enters Complex Injectables Space. The company receives FDA Approval for Generic Actos Tablets, and Generic Celebrex Capsules.

In 2015, the company launches Generic DIOVANr Tablets. The company receives FDA Approval for Generic Vancocin Capsules. During the year under review, the company and Celon announce Strategic Development and Licensing Agreement for Generic Advair Diskus. The company and Rotary Join Hands to Combat Tuberculosis in Mumbai. The company introduces generic hypertension drug in US. The company also acquires Biocom in Russia during the year under review.

On 24 July 2015, Lupin announced that it has entered into a strategic asset purchase agreement with TEMMLER PHARMA GMBH & CO. KG (Temmler), a part of the Aenova Group, one of the world's largest pharmaceutical contract manufacturers, to acquire Temmler's specialty product portfolio subject to certain closing conditions. On 7 August 2015, Lupin announced the opening of its new Center of Excellence for Inhalation Research in Coral Springs, Florida.

On 14 October 2015, Lupin and Boehringer Ingelheim announced a joint strategic alliance for co-marketing linagliptin, a novel Dipeptidylpeptidase-4 (DPP-4) inhibitor in India. According to the agreement, Lupin will market and sell linagliptin under a separate brand name which will be promoted by Lupin's dedicated diabetes specialty field force. Boehringer Ingelheim will continue to sell its linagliptin under the brand names Trajenta (monotherapy) and TrajentaDuo (fixed-dose combination with metformin) through its existing sales force and network.

On 9 March 2016, Lupin announced that it has completed the acquisition of privately held US based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS). Lupin had announced the acquisition on 23 July 2015. The acquisition enhances Lupin's scale in the US generic market and also broadens Lupin's pipeline in dermatology, controlled substance products and other high-value and niche generics. New Jersey based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products.

On 15 March 2016, Lupin announced that the USFDA inspected its Goa manufacturing facility and cited 9 observations. The observations were on aspects such as inadequacy and adherence to standard operating procedures. Lupin said that it is in the midst of putting together a response to address USFDA's observations.

On 26 May 2016, Lupin announced that it has received Establishment Inspection Reports (EIR) for its Mandideep and Aurangabad facilities wherein the USFDA has concluded that the inspections stand closed. The USFDA had conducted audits at Lupin's Mandideep facility from 8 to 19 February 2016 and its Aurangabad facility from 11 to 15 January 2016.

On 2 August 2016, Lupin announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. has entered into a strategic asset purchase agreement with Shionogi & Co., Ltd., Japan to acquire 21 long-listed products from the Japanese company effective 1 December 2016, subject to certain closing conditions and regulatory approvals including the transfer of marketing authorization of the products to Kyowa. The 21 products cover therapy areas such as Central Nervous System (CNS), Oncology, Cardiovascular and Anti-infectives.

On 6 October 2016, Lupin announced that its US subsidiary Lupin Pharmaceutical Inc. and MonoSol Rx, a specialty pharmaceutical company, have entered into a strategic licensing agreement wherein Lupin would develop multiple pediatric products utilizing MonoSol Rx's proprietary PharmFilm drug delivery technology. MonoSol Rx's PharmFilm technology is a drug delivery platform that provides precision dosing in the form of a quick-dissolving, taste-masked and easy-to-administer dissolvable film.

On 13 October 2016, Lupin and Boehringer Ingelheim announced a strategic alliance to co-market Empagliflozin, a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor in India. According to the agreement, Lupin will market and sell Empagliflozin under a separate brand name Gibtulio which will be promoted by Lupin's specialty field force. Boehringer Ingelheim will continue to sell Empagliflozin under the brand name Jardiance through its existing sales force and network. Headquartered in Ingelheim, Germany, Boehringer Ingelheim is one of the world's leading pharmaceutical companies.

On 11 November 2016, Lupin announced the launch of a novel Iron Isomaltoside 1000 injectable iron formulation under two brand names ISOFER and JILAZO in India. Lupin acquired the exclusive rights to market, distribute and sell the novel injectable formulation from Denmark based Pharmacosmos A/S. Iron Isomaltoside 1000 is indicated for the treatment of iron deficiency when oral iron preparations are ineffective or cannot be used and when there is a clinical need to deliver iron rapidly.

On 1 December 2016, Lupin and Eli Lilly and Company (India) Pvt. Ltd. (Lilly) announced an expansion of their partnership in India with the launch of Eglucent, a new brand of Lilly's rapid-acting insulin analog Lispro. Eglucent is indicated for the treatment of patients with diabetes mellitus. According to the agreement, Lupin will market and sell Eglucent through its own specialty field force while Lilly will be responsible for manufacturing and import. Lilly will continue to sell Lispro under the brand name Humalog through its existing channels.

On 27 February 2017, Lupin announced that its Japanese subsidiary Kyowa Pharmaceutical Industry Co., Ltd. and Astellas Pharma Inc. have entered into an agreement providing Kyowa the exclusive right to distribute and promote extended-release tablets of quetiapine fumarate in Japan. Astellas submitted a new drug application (NDA) with the Ministry of Health, Labour and Welfare in Japan for extended-release tablets of quetiapine fumarate for the indication of improvement of depressive symptoms associated with bipolar disorder.

On 16 May 2017, Lupin announced that it has acquired the rights to market, promote and distribute Eli Lilly and Company's Erectile Dysfunction (ED) product, Cialis in India through its specialty field force. On 21 July 2017, Lupin announced the successful completion of a PAI inspection (Prior Approval Inspection) carried out by the USFDA at its Goa manufacturing facility without any observations. On 18 July 2017, Lupin announced the successful completion of a GMP inspection as well as a PAI inspection (Prior Approval Inspection) carried out by the USFDA at its Pithampur, Madhya Pradesh manufacturing facility - Unit 1 without any observations.

On 31 July 2017, Lupin announced the completion of a PAI inspection (Prior Approval Inspection) carried out by the USFDA at its Aurangabad, Maharashtra manufacturing facility with one 483 observation. The observation was procedural in nature and corrected during the inspection itself.

On 11 October 2017, Lupin announced that its US subsidiary, Lupin, Inc., has acquired Symbiomix Therapeutics, LLC, a privately held company focused on bringing innovative therapies to market for gynecologic infections that can have serious health consequences. The acquisition has been made for a cash consideration of USD 150 million including a USD 50 million upfront and other time-based payments. In addition, there are sales based contingent payments. Lupin said that the acquisition was funded from internal funds.

On 7 November 2017,Lupin announced that the company has received a warning letter from the USFDA for its formulation manufacturing facilities at Goa and Indore (Pithampur Unit II). Lupin said that there will be no disruption of existing product supplies from either of these two locations. However, there will likely be a delay of new product approvals from these two facilities, Lupin said. The company said that it plans to address the concerns raised by the USFDA expeditiously and will work with the USFDA to resolve these issues at the earliest.

As on 31 March 2018, the Company had 33 subsidiaries and a joint venture.

Pursuant to the application made to the Registrar of Companies (ROC'), Bangalore, by Novel Clinical Research (India) Pvt. Ltd., wholly-owned subsidiary of the Company, for removal of its name from the Register of Companies w.e.f. 27 March 2018, the ROC, vide its Order dated 08 December 2018, struck-off the name of the company from the Register of Companies. As part of restructuring, Lupin Ukraine LLC, Ukraine and Gavis Pharmaceuticals, LLC, USA, wholly-owned subsidiaries of the Company, were liquidated effective 07 February 2019 and 26 March 2019, respectively.

As on 31 March 2019, the Company had 31 subsidiaries and a joint venture.

During the FY2020,the company divested its entire stake in Kyowa Criticare Co Ltd,Japan and Kyowa Pharmaceutical Industry Co Ltd,Japan,effective 30 September 2019 and 09 December 2019 respectively. Consequently both entities ceased to be subsidiaries of the company.

As part of internal restructuring on 02 October 2019,Nanomi,B.V.Netherlands,wholly owned subsidiary of the company,was merged with Lupin Holdings,B.V.Netherlands,wholly owned subsidiary of the company,effective 01 April 2019 and its name was changed to Nanomi,B.V.Netherlands.

The name of Lupin IP Ventures Inc,USA was changed to Lupin Management Inc,USA effective from 10 March 2020.

As on 31 March 2020, the Company had 26 subsidiaries and a joint venture.

As part of restructuring, Lupin Middle East FZ-LLC, UAE and Lupin Japan & Asia Pacific K.K., Japan were liquidated, effective 02 July 2020 and 17 December 2020, respectively. Lupin GmbH, Switzerland was merged with Lupin Atlantis Holdings SA, Switzerland, effective 21 September 2020.

As part of business expansion, Lupin Biologics Limited, India and Lupin Oncology Inc., USA were incorporated on 28 January 2021 and 15 March 2021, respectively, as wholly owned subsidiaries of the Company.

As on 31 March 2021, the Company had 25 subsidiaries and a joint venture.

As on March 31, 2022, the Company had 28 subsidiaries and a joint venture.

On 03 February 2022, the Company acquired Southern Cross Pharma Pty. Limited, in Australia, as its wholly owned subsidiary. It acquired brand portfolios from Anglo-French Drugs & Industries Limited and its Associates in April 2022.

In FY 2022, it closed an alliance with Foncoo Pharmaceutical Co. in China to commercialize CNS medications, to continue offering affordable and accessible healthcare to the world.

In FY 2022, the Company had three US FDA site re-inspections and its Goa facility was upgraded allowing to introduce new product from this site.

In FY 2023, the Company introduced first Metered Dose Inhaler Luforbec and launched the orphan drug 'Namuscla'. Also, it acquired Medisol in France to enhance its injectables franchise. In FY23, the Company expanded Specialty business portfolio by incorporating two inhalation products, Xopenex and Brovana, which were acquired from Sunovion in October 2022.

In 2024, Lupin launched Lupin Digital Health (LDH), marking its foray into the burgeoning field of Digital Therapeutics (DTx). It launched Lyfe HF, catering specifically to patients dealing with heart failure. The Company had a strategic carve in API business, encompassing the manufacturing sites at Dabhasa and Vizag, as well as Fermentation and Enzymatic research at Lupin Research Park - Pune, to form its subsidiary, Lupin Manufacturing Solutions. A key launch was Tiotropium, the first approved generic version of Spiriva hand inhaler in the
U.S. and Canada in 2024.

Parent organization Indian Private
NSE symbol LUPIN
Founded 1983
stock

Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Share Price of Lupin Ltd?

Answer Field

The share price of Lupin Ltd for NSE is ₹ 2095.6 and for BSE is ₹ 2094.65.

What is the Market Cap of Lupin Ltd?

Answer Field

The market cap of Lupin Ltd for NSE is ₹ 9,54,92.08 Cr. and for BSE is ₹ 9,54,48.78 Cr. as of now.

What is the 52 Week High and Low of Lupin Ltd?

Answer Field

The 52 Week High and Low of Lupin Ltd for NSE is ₹ 2402.90 and ₹ 1493.30 and for BSE is ₹ 2403.45 and ₹ 1493.75.

How to Buy Lupin Ltd share?

Answer Field

You can trade in Lupin Ltd shares with Bajaj Broking by opening a Demat Account.

What is 1 year return for Lupin Ltd?

Answer Field

The 1 year returns on the stock has been 27.32%.

What is the Current Share Price of Lupin Ltd?

Answer Field

Lupin Ltd share price is for NSE ₹ 2095.6 & for BSE ₹ 2094.65 as on Apr 30 2025 03:30 PM.

What is the Market Cap of Lupin Ltd Share?

Answer Field

The market cap of Lupin Ltd for NSE ₹ 9,54,92.08 & for BSE ₹ 9,54,48.78 as on Apr 30 2025 03:30 PM.

What is the P/E Ratio of Lupin Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM the price-to-earnings (PE) ratio for Lupin Ltd share is 31.19.

What is the PB ratio of Lupin Ltd Share?

Answer Field

As on Apr 30 2025 03:30 PM, the price-to-book (PB) ratio for Lupin Ltd share is 481.38.

How to Buy Lupin Ltd Share?

Answer Field

You can trade in Lupin Ltd shares with Bajaj Broking by opening a demat account.

How to Buy Lupin Ltd Share on Bajaj Broking App?

Answer Field

To buy Lupin Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “Lupin Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|